Navigation Links
Researchers discover mechanism for multiplying adult stem cells

While the field of human embryonic stem cell research receives a tremendous amount of public attention, many scientists are also exploring the potential of adult stem cells for possible therapies. But this field raises other difficulties. Although adult stem cell research isn't fraught with the controversies that surround embryonic stem cells, adult stem cells are extremely difficult to isolate and then to multiply in a lab dish. Now, as reported in the May 6 issue of the journal Cell, researchers in the lab of Whitehead Institute Member Rudolf Jaenisch have discovered a mechanism that might enable scientists to multiply adult stem cells quickly and efficiently.

"These findings provide us with a new way of looking at adult stem cells and for possibly exploiting their therapeutic potential," says Jaenisch, who also is a professor of biology at MIT.

This research focuses on a gene called Oct4, a molecule that is known to be active in the early embryonic stage of an organism. Oct4's primary function is to keep an embryo in an immature state. It acts as a gatekeeper, preventing the cells in the embryo from differentiating into tissue-specific cells. While Oct4 is operating, all the cells in the embryo remain identical, but when Oct4 shuts off, the cells begin growing into, say, heart or liver tissue.

Konrad Hochedlinger, a post-doctoral researcher in Jaenisch's lab, was experimenting with the Oct4 gene, curious to see what happens in laboratory mice when the gene is reactivated in adult tissue where it has long been dormant. Hochedlinger found that when he switched the gene on, the mice immediately formed tumors in the gut and in the skin where the gene was active. When he switched the gene off, the tumors subsided, demonstrating that the process is reversible.

Discovering that simply flipping a single gene on and off has such an immediate effect on a tumor was unexpected, even though Oct4 is known to be active in certain forms of testicul
'"/>

Source:Whitehead Institute for Biomedical Research


Page: 1 2

Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. Researchers reveal the infectious impact of salmon farms on wild salmon
5. Researchers identify target for cancer drugs
6. Researchers discover molecule that causes secondary stroke
7. Researchers find missing genes of ancient organism
8. Researchers trace evolution to relatively simple genetic changes
9. Researchers add new tool to tumor-treatment arsenal
10. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
11. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain

Post Your Comments:
(Date:11/9/2009)...9, 2009 / b3c newswire / - Today, TNO, a Dutch ...an American organization for contract research and...ned a letter of intent with regard to TNOs dynamic...r of intent proposes a collaboration in which Seve...lization in North America. The TIM systems will be...
(Date:11/9/2009)...stry leaders from around the world will gather in ...lecular Targets and Cancer Therapeutics Internatio...information on important cancer therapies in devel...reat it effectively we need a greater understandin...r level," said Lewis Cantley, Ph.D., director of t...
(Date:11/8/2009)...hers at Purdue University have discovered a new ap...l cord injuries using nano-spheres that could be i..., The synthetic "copolymer micelles" are drug-de... roughly 100 times smaller than the diameter of a ... how to deliver drugs for cancer treatment and oth...
Breaking Biology News(10 mins):TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services 2Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3InVitria Reports Successful Cell Culture Performance of Zap CHO a Defined and Cost Effective CHO Cell Culture Media Supplement 60242 1InVitria Reports Successful Cell Culture Performance of Zap CHO a Defined and Cost Effective CHO Cell Culture Media Supplement 60242 2NeuroVasx Announces First Case of cPAX Aneurysm Treatment System in Spain 60238 1NeuroVasx Announces First Case of cPAX Aneurysm Treatment System in Spain 60238 2NeuroVasx Announces First Case of cPAX Aneurysm Treatment System in Spain 60238 3Health Partners to Offer Health Insurance Through the Childrens Health Insurance Program 60234 1Health Partners to Offer Health Insurance Through the Childrens Health Insurance Program 60234 2
... When Yadong Wang, a chemist by training, first ve...idn,t know that his peers would have considered hi...cuits use electrical signals often conducted by ne...te between the brain and the rest of the body, he ...ed to repair a broken circuit. The neurotransmitte...
... University of Manchester researchers are recruiti...?commonly known as sciatica ?in the first ever stu...their condition. , Dr Christopher McCarthy and his...n Science need 30 volunteers aged 22-55 who have h...nt and have not had previous spinal surgery. , ...
... Using the latest in high tech tools, researchers ...edictive of chronic lung rejection up to 20 months...patients have the highest mortality rate of organ ...nvestigator and pulmonologist Chris Wendt. Current...splants will fail, and when signs of chronic rejec...
Other Biology News:Dopamine used to prompt nerve tissue to regrow 2Proteins may predict lung transplant rejection 2Proteins may predict lung transplant rejection 3
(Date:11/6/2009)...Newswire-FirstCall/ -- Helix BioPharma Corp. (TSX,...that John Docherty, president and chief operating ...h annual Investor Summit on November 10, 2009 at 4... Docherty will provide an overview of the Company,... Topical Interferon Alpha-2b. The slide show port...
(Date:11/6/2009)...PRNewswire-FirstCall/ -- ,, 3Q09 Corporate H...TM) E.U. Marketing Authorization to Astellas Pharm...rcial readiness activities Expanded management te...; and Director, Commercial Operations Appointed B...Committee chairman , Upcoming 2009 Mileston...
(Date:11/6/2009)...Newswire/ -- Intarcia Therapeutics, Inc. delivered...74; continuous delivery of exenatide) program for ...al Diabetes Technology Meeting in San Francisco, C...nh/20050301/SFTU126LOGO ) ,, Continuous Subcu...Plasma Glucose, HbA1c and Reduces Weight in a 28-d...
(Date:11/5/2009)...PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GN... third quarter ended September 30, 2009. GenVec re...) for the three months ended September 30, 2009 co...are) in the comparable quarter of 2008. For the ni...oss was $14.1 million ($0.15 per share), compared ...
Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
...RDAM, The Netherlands, February 18 ,Amsterdam Mole...e field of,human gene therapy, announced today tha...ll year 2008 on Tuesday, February 24, 2009 at 7:00...results, the Company will,conduct a conference cal... for the Netherlands is 0800-949-4166 (toll free)....
...b., Feb. 18 Transgenomic Inc. (OTC Bulletin Board...hat: Transgenomic Inc. Fourth Quarter 2008 Ear...en: Wednesday, February 25, 2009 @ 5:00 p.m. E...vents.asp?id=6 , How: Live over the Intern... address above., , , To access the call via te...
...ES, Feb. 18 The Board of Directors wishes to conf...y 4, 2009 it resolved to file a Form 15 with effec...t require the approval of stockholders but in the ...olders informed the Board is making this Release. ...ompany from its United States Securities and Excha...
Other Biology Technology:AMT to Release Full Year 2008 Results on February 24, 2009 2Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2008 Earnings Release Conference Call Webcast 2EESTECH Inc - Release From SEC Filing 2EESTECH Inc - Release From SEC Filing 3EESTECH Inc - Release From SEC Filing 4
SILVER SEQUENCE Staining Reagents from Promega
Sheep Anti-Decorin Polyclonal Antibody, Unconjugated from Abcam
Mouse Complement from Equitech-Bio
...S-4P, all Programmable and Digital Orbital Shaker.... been redesigned to make every day use even easier...memory for up to 4 different programs. Its easy re...am. Furthermore, the VSOS-4P has a pulse operation...
Biology Products: